Shares of Epizyme Inc. (EPZM) have lost 50% of their value over the last 7 months compared to the 1.2 % gain of the iShares Nasdaq Biotechnology ETF (IBB) index during the same period.
Epizyme is a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer and other serious diseases. Epigenetic therapy is a novel therapeutic approach that focuses on changes in DNA expression without altering the makeup of the genes themselves.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.